Review



human ctgf  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress human ctgf
    a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated <t>with</t> <t>recombinant</t> human <t>CTGF</t> (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control siRNA (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, NC-siRNA; siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.
    Human Ctgf, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctgf/CCN2%2FCTGF%2C+Human/pmc13066582-324-11-17
    Average 94 stars, based on 3 article reviews
    human ctgf - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "Role of CTGF-LRP1 in impaired healing of cesarean section incisions"

    Article Title: Role of CTGF-LRP1 in impaired healing of cesarean section incisions

    Journal: Nature Communications

    doi: 10.1038/s41467-026-69747-9

    a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated with recombinant human CTGF (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control siRNA (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, NC-siRNA; siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.
    Figure Legend Snippet: a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated with recombinant human CTGF (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control siRNA (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, NC-siRNA; siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.

    Techniques Used: Derivative Assay, Control, Recombinant, Western Blot, Expressing, Transfection, In Vitro

    Related Articles

    Functional Assay:

    Article Title: Role of CTGF-LRP1 in impaired healing of cesarean section incisions.
    Article Snippet: .. For functional assays, cells were treated for 48 hours with recombinant human CTGF (rhCTGF; HY-P70106, MCE), PD98059 (MEK/ERK inhibitor, HY-12028, MCE), or C16-PAF (MEK/ERK agonist, HY-108635, MCE). .. The human uterine fibroblast (HUF) and rat uterine fibroblast (RUF) were obtained from Procell Biological Technology in China.

    Article Title: Role of CTGF-LRP1 in impaired healing of cesarean section incisions
    Article Snippet: .. For functional assays, cells were treated for 48 hours with recombinant human CTGF (rhCTGF; HY- P70106 , MCE), PD98059 (MEK/ERK inhibitor, HY-12028, MCE), or C16-PAF (MEK/ERK agonist, HY-108635, MCE). .. The human uterine fibroblast (HUF) and rat uterine fibroblast (RUF) were obtained from Procell Biological Technology in China.

    Recombinant:

    Article Title: Role of CTGF-LRP1 in impaired healing of cesarean section incisions.
    Article Snippet: .. For functional assays, cells were treated for 48 hours with recombinant human CTGF (rhCTGF; HY-P70106, MCE), PD98059 (MEK/ERK inhibitor, HY-12028, MCE), or C16-PAF (MEK/ERK agonist, HY-108635, MCE). .. The human uterine fibroblast (HUF) and rat uterine fibroblast (RUF) were obtained from Procell Biological Technology in China.

    Article Title: Role of CTGF-LRP1 in impaired healing of cesarean section incisions
    Article Snippet: .. For functional assays, cells were treated for 48 hours with recombinant human CTGF (rhCTGF; HY- P70106 , MCE), PD98059 (MEK/ERK inhibitor, HY-12028, MCE), or C16-PAF (MEK/ERK agonist, HY-108635, MCE). .. The human uterine fibroblast (HUF) and rat uterine fibroblast (RUF) were obtained from Procell Biological Technology in China.



    Similar Products

    89
    Multi Sciences (Lianke) Biotech Co Ltd human ctgf elisa kit
    Human Ctgf Elisa Kit, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 89/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctgf/Human+CTGF+ELISA+Kit/custom%40ek198%4042764425
    Average 89 stars, based on 1 article reviews
    human ctgf elisa kit - by Bioz Stars, 2026-10
    89/100 stars
      Buy from Supplier

    94
    MedChemExpress human ctgf
    a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated <t>with</t> <t>recombinant</t> human <t>CTGF</t> (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control siRNA (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, NC-siRNA; siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.
    Human Ctgf, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctgf/CCN2%2FCTGF%2C+Human/pmc13066582-324-11-17
    Average 94 stars, based on 1 article reviews
    human ctgf - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Bio-Techne corporation human ctgf/ccn2 duoset elisa
    a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated <t>with</t> <t>recombinant</t> human <t>CTGF</t> (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control siRNA (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, NC-siRNA; siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.
    Human Ctgf/Ccn2 Duoset Elisa, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctgf/Human+CTGF%2FCCN2+DuoSet+ELISA/bio-techne+corporation___dy9190-05
    Average 94 stars, based on 1 article reviews
    human ctgf/ccn2 duoset elisa - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    93
    R&D Systems length standard
    a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated <t>with</t> <t>recombinant</t> human <t>CTGF</t> (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control siRNA (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, NC-siRNA; siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.
    Length Standard, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctgf/Recombinant+Human+CTGF%2FCCN2+Protein%2C+CF/us12600770-686-14-20
    Average 93 stars, based on 1 article reviews
    length standard - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    R&D Systems length human ctgf
    a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated <t>with</t> <t>recombinant</t> human <t>CTGF</t> (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control siRNA (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, NC-siRNA; siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.
    Length Human Ctgf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctgf/Recombinant+Human+CTGF%2FCCN2+Protein%2C+CF/us12600770-675-44-47
    Average 93 stars, based on 1 article reviews
    length human ctgf - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    94
    MedChemExpress nc sirna
    a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated with recombinant human CTGF (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control <t>siRNA</t> (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, <t>NC-siRNA;</t> siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.
    Nc Sirna, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctgf/CCN2%2FCTGF%2C+Human/pmc13066582-331-10-25
    Average 94 stars, based on 1 article reviews
    nc sirna - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress rhctgf
    a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated with recombinant human CTGF (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control <t>siRNA</t> (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, <t>NC-siRNA;</t> siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.
    Rhctgf, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctgf/CCN2%2FCTGF%2C+Human/pm41764198-266-21-23
    Average 94 stars, based on 1 article reviews
    rhctgf - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    93
    R&D Systems ctgf standard protein
    a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated with recombinant human CTGF (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control <t>siRNA</t> (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, <t>NC-siRNA;</t> siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.
    Ctgf Standard Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctgf/Recombinant+Human+CTGF%2FCCN2+Protein%2C+CF/pm41456782-93-7-12
    Average 93 stars, based on 1 article reviews
    ctgf standard protein - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    Image Search Results


    a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated with recombinant human CTGF (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control siRNA (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, NC-siRNA; siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.

    Journal: Nature Communications

    Article Title: Role of CTGF-LRP1 in impaired healing of cesarean section incisions

    doi: 10.1038/s41467-026-69747-9

    Figure Lengend Snippet: a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated with recombinant human CTGF (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control siRNA (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, NC-siRNA; siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.

    Article Snippet: For functional assays, cells were treated for 48 hours with recombinant human CTGF (rhCTGF; HY- P70106 , MCE), PD98059 (MEK/ERK inhibitor, HY-12028, MCE), or C16-PAF (MEK/ERK agonist, HY-108635, MCE).

    Techniques: Derivative Assay, Control, Recombinant, Western Blot, Expressing, Transfection, In Vitro

    a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated with recombinant human CTGF (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control siRNA (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, NC-siRNA; siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.

    Journal: Nature Communications

    Article Title: Role of CTGF-LRP1 in impaired healing of cesarean section incisions

    doi: 10.1038/s41467-026-69747-9

    Figure Lengend Snippet: a Schematic of experimental groups: fibroblasts derived from Adjacent, Control, and Niche tissues were treated with recombinant human CTGF (rhCTGF). b Western blot analysis of Collagen I and III in fibroblasts following rhCTGF treatment. c Schematic of transcriptomic analysis in human uterine fibroblasts (HUFs) with modulated LRP1 expression under rhCTGF stimulation. d Collagen I and III expression in HUFs transfected with control siRNA (siNC) or LRP1 siRNA (siLRP1) and stimulated with rhCTGF. e Volcano plot showing differentially expressed genes (DEGs) between rhCTGF-treated siNC and siLRP1 HUFs. f GO analysis indicating suppression of ERK and WNT pathways in LRP1-silenced, rhCTGF-treated HUFs. g Western blot of phosphorylated ERK in siNC- or siLRP1-transfected HUFs treated with rhCTGF. h Phospho-ERK levels in Adjacent, Control, and Niche fibroblasts treated with rhCTGF. i Western blot analysis of Collagen I, Collagen III, and phospho-β-catenin in HUFs transfected with siNC or siLRP1 and treated with rhCTGF in combination with PD98059 (MEK1 inhibitor) or PAF-C16 (ERK1/2 activator). j Collagen I, Collagen III, and phospho-β-catenin expression in Adjacent, Control, and Niche fibroblasts treated with rhCTGF with or without PD98059 or PAF-C16. All in vitro experiments are performed in three independent replicates. Adjacent, adjacent myometrium tissue of niche; Control, well-healed cesarean scar tissue; Niche, niche tissue; HUF, human uterine fibroblasts; siNC, NC-siRNA; siLRP1, LRP1-siRNA. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u --.

    Article Snippet: Following transfection with LRP1 siRNA, NC siRNA, lrp1 siRNA or nc siRNA for 48 hours, the cells were subsequently incubated with rhCTGF (HY- P70106 , MCE), PD98059 (HY-12028, MCE), or C16-PAF (HY-108635, MCE) for 48 hours.

    Techniques: Derivative Assay, Control, Recombinant, Western Blot, Expressing, Transfection, In Vitro

    a Experimental timeline for the establishment and treatment of the rat uterine scar model. b Schematic illustration and gross anatomical image of the rat uterine scar model. c H&E staining of uterine horns on days 14 and 30 post-surgery across sham, PBS, and rhctgf-treated groups ( n = 8 uterine horns per group). Red arrows indicate scar repair sites. Scale bars = 500 μm. d Immunohistochemical staining for α-smooth muscle actin (α-SMA) at incision sites on days 14 and 30. Red arrows mark the repaired myometrial regions. Scale bars = 500 μm. The regenerating myometrium originated from residual tissue flanking the incision and appeared thin, irregular, and fragmented. e Masson’s trichrome staining assessing collagen deposition at incision sites on days 14 and 30. Scale bars = 200 μm. Quantitative analysis of collagen fiber area was performed. f , g Efficiency of lrp1 knockdown in rat uterine fibroblasts assessed at the mRNA level. RT-qPCR and Western blot analyses show Collagen I and III expression in fibroblasts transfected with nc-siRNA or lrp1-siRNA and treated with rhctgf. Data are shown as mean ± SEM. The p values were calculated using a two-tailed unpaired Student’s t -test. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u .

    Journal: Nature Communications

    Article Title: Role of CTGF-LRP1 in impaired healing of cesarean section incisions

    doi: 10.1038/s41467-026-69747-9

    Figure Lengend Snippet: a Experimental timeline for the establishment and treatment of the rat uterine scar model. b Schematic illustration and gross anatomical image of the rat uterine scar model. c H&E staining of uterine horns on days 14 and 30 post-surgery across sham, PBS, and rhctgf-treated groups ( n = 8 uterine horns per group). Red arrows indicate scar repair sites. Scale bars = 500 μm. d Immunohistochemical staining for α-smooth muscle actin (α-SMA) at incision sites on days 14 and 30. Red arrows mark the repaired myometrial regions. Scale bars = 500 μm. The regenerating myometrium originated from residual tissue flanking the incision and appeared thin, irregular, and fragmented. e Masson’s trichrome staining assessing collagen deposition at incision sites on days 14 and 30. Scale bars = 200 μm. Quantitative analysis of collagen fiber area was performed. f , g Efficiency of lrp1 knockdown in rat uterine fibroblasts assessed at the mRNA level. RT-qPCR and Western blot analyses show Collagen I and III expression in fibroblasts transfected with nc-siRNA or lrp1-siRNA and treated with rhctgf. Data are shown as mean ± SEM. The p values were calculated using a two-tailed unpaired Student’s t -test. Source data are provided as a Source Data file. Created in BioRender. He, C. (2025) https://BioRender.com/krpej6u .

    Article Snippet: Following transfection with LRP1 siRNA, NC siRNA, lrp1 siRNA or nc siRNA for 48 hours, the cells were subsequently incubated with rhCTGF (HY- P70106 , MCE), PD98059 (HY-12028, MCE), or C16-PAF (HY-108635, MCE) for 48 hours.

    Techniques: Staining, Immunohistochemical staining, Knockdown, Quantitative RT-PCR, Western Blot, Expressing, Transfection, Two Tailed Test